Research progress of PTHrP analogue abaloparide in osteoporosis

doi:10.3877/cma.j.issn.2096-0263.2021.02.009

Abstract

Abstract:

Abaloparatide, the amino acid synthesis analogue of human parathyroid hormone-related protein (PTHrP), is a novel selective activator of the parathyroid hormone-1 receptor signaling pathway, which can increase bone density and bone mass, improve bone microstructure and strength, and is the second bone synthesis drug after Teriptide.Many preclinical and basic studies have found that abaloparatide is effective in the treatment of postmenopausal osteoporosis, providing a new treatment strategy for postmenopausal osteoporosis, but a large number of studies and large animal studies are still needed to better verify the biosafsafety of PTHrP analogue in the treatment of osteoporosis. This article reviews the progress in the study of the bone synthesis drug PTHrP analogue abaloparatide in patients with osteoporosis.

Key words: Osteoporosis, PTHrP analog, Abaloparatide, Teriparatide, Literature review

Xue Wen, Hong Sun, Hong Wang, Miao Liu, Xu Ning. Research progress of PTHrP analogue abaloparide in osteoporosis[J]. Chinese Journal of Geriatric Orthopaedics and Rehabilitation(Electronic Edition), 2021, 07(02): 117-121.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhlngkykfdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2096-0263.2021.02.009

https://zhlngkykfdzzz.cma-cmc.com.cn/EN/Y2021/V07/I02/117

References 51

1	Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis [J]. Am J Med, 1993, 94(6): 646-650.
2	Burge R, Dawson-Hughes B, Solomon D H, et al. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025 [J]. J Bone Miner Res, 2007, 22(3): 465-475.
3	Eastell R, Rosen CJ, Black DM, et al. Pharmacological management of osteoporosis in postmenopausal women: an endocrine society* clinical practice guideline [J]. J Clin Endocrinol Metab, 2019, 104(5): 1595-1622.
4	Chew CK, Clarke BL. Abaloparatide: recombinant human PTHrP (1-34) anabolic therapy for osteoporosis [J]. Maturitas, 2017, 97: 53-60
5	Michael RM, MD, Nicholas CH, et al. Effects of abaloparatide on bone mineral density and risk of fracture in postmenopausal women aged 80 years or older with osteoporosis[J]. Menopause, 2018, 25(7): 767-771.
6	Lorentzon M. Treating osteoporosis to prevent fractures: current concepts and future developments [J]. J Intern Med, 2019, 285(4): 381-394.
7	Eastell R, Rosen CJ. Response to letter to the editor: "pharmacological management of osteoporosis in postmenopausal women: an endocrine society clinical practice guideline" [J]. J Clin Endocrinol Metab, 2019, 104(8): 3537-3538.
8	Anagnostis P, Paschou S, Mintziori G, et al. Drug holidays from bisphosphonates and denosumab in postmenopausal osteoporosis: EMAS position statement [J]. Maturitas, 2017, 101: 23-30.
9	Silverman S, Langdahl BL, Fujiwara S, et al. Reduction of hip and other fractures in patients receiving teriparatide in Real-World clinical practice: integrated analysis of four prospective observational studies [J]. Calcif Tissue Int, 2019, 104(2): 193-200.
10	Sahbani K, Cardozo CP, Bauman WA, et al. Abaloparatide exhibits greater osteoanabolic response and higher cAMP stimulation and β-arrestin recruitment than teriparatide [J]. Physiol Rep, 2019, 7(19): e14225.
11	Anagnostis P, Gkekas NK, Potoupnis M, et al. New therapeutic targets for osteoporosis [J]. Maturitas, 2019, 120: 1-6.
12	Beall DP, Feldman RG, Gordon ML, et al. Patients with prior vertebral or hip fractures treated with teriparatide in the Direct Assessment of Nonvertebral Fractures in Community Experience (DANCE) observational study [J]. Osteoporos Int, 2016, 27(3): 1191-1198.
13	Cheloha RW, Gellman SH, Vilardaga J. PTH receptor-1 signalling-mechanistic insights and therapeutic prospects [J]. Nat Rev Endocrinol, 2015, 11(12): 712-724.
14	Fischer J, Aulmann A, Dexheimer V, et al. Intermittent PTHrP(1-34) exposure augments chondrogenesis and reduces hypertrophy of mesenchymal stromal cells [J]. Stem Cells Dev, 2014, 23(20): 2513-2523.
15	Kanis JA, Odén A, Mccloskey EV, et al. A systematic review of hip fracture incidence and probability of fracture worldwide [J]. Osteoporos Int, 2012, 23(9): 2239-2256.
16	Panula J, Pihlajamäki H, Mattila VM, et al. Mortality and cause of death in hip fracture patients aged 65 or older - a population-based study [J]. BMC Musculoskelet Disord, 2011, 12(1): 105.
17	Osteoporosis Foundation Facts Statistics. International Osteoporosis Foundation website. URL
18	Leslie WD, Metge CJ, Azimaee M, et al. Direct costs of fractures in Canada and trends 1996-2006: a population-based cost-of-illness analysis [J]. J Bone Miner Res, 2011, 26(10): 2419-2429.
19	Ensrud K, Crandall CJ. Osteoporosis [J]. Ann Intern Med, 2017, 167(3): ITC17-ITC32.
20	Saag KG, Williams SA, Wang Y, et al. Effect of abaloparatide on bone mineral density and fracture incidence in a subset of younger postmenopausal women with osteoporosis at high risk for fracture [J]. Clin Ther, 2020, 42(6): 1099-1107.e1.
21	Mccauley LK, Martin TJ. Twenty-five years of PTHrP progress: from cancer hormone to multifunctional cytokine [J]. J Bone Miner Res, 2012, 27(6): 1231-1239.
22	Revollo L, Kading J, Jeong SY, et al. N-cadherin restrains PTH activation of Lrp6/β-catenin signaling and osteoanabolic action [J]. J Bone Miner Res, 2015, 30(2): 274-285.
23	Silva BC, Bilezikian JP. Parathyroid hormone: anabolic and catabolic actions on the skeleton [J]. Curr Opin Pharmacol, 2015, 22(10): 41-50.
24	de Castro L F, Lozano D, Portal-Nunez S, et al. Comparison of the skeletal effects induced by daily administration of PTHrP (1-36) and PTHrP (107-139) to ovariectomized mice[J]. J Cell Physiol,2012,227(4):1752-1760.
25	Minisola S, Cipriani C, Occhiuto M, et al. New anabolic therapies for osteoporosis[J]. Intern Emerg Med,2017,12(7):915-921.
26	Shirley M. Abaloparatide: first global approval [J]. Drugs, 2017, 77(12): 1363-1368.
27	Hattersley G, Dean T, Corbin BA, et al. Binding selectivity of abaloparatide for PTH-Type-1-Receptor conformations and effects on downstream signaling [J]. Endocrinology, 2016, 157(1): 141-149.
28	Xu J, Rong H, Ji H, et al. Effects of different dosages of parathyroid hormone-related protein 1-34 on the bone metabolism of the ovariectomized rat model of osteoporosis [J]. Calcif Tissue Int, 2013, 93(3): 276-287.
29	Varela A, Chouinard L, Lesage E, et al. One year of abaloparatide*, a selective activator of the PTH1 receptor, increased bone formation and bone mass in osteopenic ovariectomized rats without increasing bone resorption [J]. J Bone Miner Res, 2017, 32(1): 24-33.
30	Doyle N, Varela A, Haile S, et al. Abaloparatide, a novel PTH receptor agonist, increased bone mass and strength in ovariectomized cynomolgus monkeys by increasing bone formation without increasing bone resorption [J]. Osteoporos Int, 2018, 29(3): 685-697.
31	Gonnelli S, Caffarelli C. Abaloparatide [J]. Clin Cases Miner Bone Metab, 2016, 13(2): 106-109.
32	Yusuf A, Cummings SR, Watts NB, et al. Real-world effectiveness of osteoporosis therapies for fracture reduction in post-menopausal women [J]. Arch Osteoporos, 2018, 13(1): 33.
33	Miller PD, Hattersley G, Riis BJ, et al. Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis a randomized clinical trial [J]. JAMA, 2016, 316(7): 722-733.
34	Mccloskey EV, Johansson H, Oden A, et al. The effect of Abaloparatide-SC on fracture risk is Independent of baseline FRAX fracture probability: a post Hoc analysis of the ACTIVE study [J]. J Bone Miner Res, 2017, 32(8): 1625-1631.
35	Sleeman A, Clements JN. Abaloparatide: a new pharmacological option for osteoporosis [J]. Am J Health Syst Pharm, 2019, 76(3): 130-135.
36	Leder B Z, Mitlak B, Hu M Y, et al. Effect of Abaloparatide vs Alendronate on Fracture Risk Reduction in Postmenopausal Women With Osteoporosis[J]. J Clin Endocrinol Metab,2020,105(3).
37	Bilezikian JP, Hattersley G, Mitlak BH, et al. Abaloparatide in patients with mild or moderate renal impairment: results from the ACTIVE phase 3 trial [J]. Curr Med Res Opin, 2019, 35(12): 2097-2102.
38	Watts NB, Hattersley G, Fitzpatrick LA, et al. Abaloparatide effect on forearm bone mineral density and wrist fracture risk in postmenopausal women with osteoporosis [J]. Osteoporos Int, 2019, 30(6): 1187-1194.
39	Cosman F. The evolving role of anabolic therapy in the treatment of osteoporosis [J]. Curr Opin Rheumatol, 2019, 31(4): 376-380.
40	Rubin MR, Bilezikian JP. New anabolic therapies in osteoporosis [J]. Curr Opin Rheumatol, 2002, 14(4): 433-440.
41	Ma YL, Marin F, Stepan J, et al. Comparative effects of teriparatide and Strontium ranelate in the periosteum of iliac crest biopsies in postmenopausal women with osteoporosis [J]. Bone, 2011, 48(5): 972-978.
42	Miller PD, Hattersley G, Lau E, et al. Bone mineral density response rates are greater in patients treated with abaloparatide compared with those treated with placebo or teriparatide: Results from the ACTIVE phase 3 trial [J]. Bone, 2019, 120: 137-140.
43	Esbrit P, Alcaraz M J. Current perspectives on parathyroid hormone (PTH) and PTH-related protein (PTHrP) as bone anabolic therapies [J]. Biochem Pharmacol, 2013, 85(10): 1417-1423.
44	Leder BZ. Parathyroid hormone and parathyroid Hormone-Related protein analogs in osteoporosis therapy [J]. Curr Osteoporos Rep,2017, 15(2): 110-119.
45	US FDA. TymlosTM (abaloparatide) injection, for subcutaneous use: US prescribing information. 2017. Accessed 30 May 2017. URL
46	Jolette J, Attalla B, Varela A, et al. Comparing the incidence of bone tumors in rats chronically exposed to the selective PTH type 1 receptor agonist abaloparatide or PTH(1-34) [J]. Regul Toxicol Pharmacol, 2017, 86: 356-365.
47	Maycas M, Mcandrews KA, Sato AY, et al. PTHrP-Derived peptides restore bone mass and strength in diabetic mice: additive effect of mechanical loading [J]. J Bone Miner Res, 2017, 32(3): 486-497.
48	Chow S K, Leung K S, Qin J, et al. Mechanical stimulation enhanced estrogen receptor expression and callus formation in diaphyseal long bone fracture healing in ovariectomy-induced osteoporotic rats[J]. Osteoporos Int,2016,27(10):2989-3000.
49	Bortoluzzi A, Furini F, Scirè CA. Osteoarthritis and its management-Epidemiology, nutritional aspects and environmental factors [J]. Autoimmun Rev, 2018, 17(11): 1097-1104.
50	Sampson E R, Hilton M J, Tian Y, et al. Teriparatide as a chondroregenerative therapy for injury-induced osteoarthritis[J]. Sci Transl Med,2011,3(101):101r-193r.
51	Cao X, Duan Z, Yan Z, et al. miR-195 contributes to human osteoarthritis via targeting PTHrP [J]. J Bone Miner Metab, 2019, 37(4): 711-721.

[1]	The Joint Surgery Branch of the Chinese Orthopedic Association, Guangdong’s Medical Association of Osteoporosis And Bone Mineral Research, Foshan Shunde 3rd Peoele’s Hospital. Clinical intervention guideline for using of anti-osteoporosis drugs in postoperative fragile hip fractures in China (2023 Edition) [J]. Chinese Journal of Joint Surgery(Electronic Edition), 2023, 17(06): 751-764.
[2]	Yan Wang, Jianxiong Ma, Shuang Lang, Benchao Dong, Aixian Tian, Yan Li, Lei Sun, Hongzhen Jin, Bin Lu, Ying Wang, Haohao Bai, Xinlong Ma. Research progress in application of exosomes in diagnosis and treatment of osteoporosis [J]. Chinese Journal of Joint Surgery(Electronic Edition), 2023, 17(05): 673-678.
[3]	Luqiao Pu, Yongqing Xu, Baochuang Qi, Hongxin Shi, Wei Lin, Pengfei Bu, Yan Bai, Zhifang Tang, Chuan Li. Prospectus on clinical intervention guideline for anti-osteoporosis drugs in postoperative fragile hip fractures in China (2023 edition) [J]. Chinese Journal of Joint Surgery(Electronic Edition), 2023, 17(05): 747-750.
[4]	Changjiao Sun, Peng Yu, Xu Cai, Yongwei Pan. Progress of shoulder arthroplasty in patients with osteoporosis [J]. Chinese Journal of Joint Surgery(Electronic Edition), 2023, 17(02): 253-260.
[5]	Yixian Lu, Zhentao Zhang, Demeng Xia, Jialin Wang. Research progress of the regulating role and mechanism of macrophage polarization in osteoporosis [J]. Chinese Journal of Injury Repair and Wound Healing(Electronic Edition), 2023, 18(06): 538-541.
[6]	Yueqi Chen, Rui Luo, Han Xiang, Yongyan Yu, Ting Yu. The causal association between osteoporosis and periodontitis: A two-sample Mendelian randomization study [J]. Chinese Journal of Stomatological Research(Electronic Edition), 2023, 17(04): 292-298.
[7]	Chunyan Li, Jiancheng Xu, Yue Zhang, Jing Xu, Mingdong Hu. Pulmonary sarcomatoid carcinoma: a case report and review of the literature [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2023, 16(02): 195-199.
[8]	Nini Wang, Rongrong Chen, Qing Zhang, Chengshi Zhang, Donghui Cui, Jian Wu, Han Lei, Yunfeng Zhao. Primary mucinous adenocarcinoma of the lung: three cases report and literature review [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2023, 16(02): 190-194.
[9]	Juan Wang, Jun Gao, Yilan Zhou, Xiaohong Li, Bingwei Shi, Meizhen Pan. Relationship between serum IL-2, IL-17 and bone mineral density and their predictive value for osteoporosis [J]. Chinese Journal of Geriatric Orthopaedics and Rehabilitation(Electronic Edition), 2023, 09(05): 295-300.
[10]	Xi Zhang, YeQing Liu, Xueying Kang, Bingbing Sun, Yan Liu, Liye Hu, Yaru Zhou. Correlation between serum ferritin and postmenopausal osteoporosis [J]. Chinese Journal of Geriatric Orthopaedics and Rehabilitation(Electronic Edition), 2023, 09(03): 166-171.
[11]	Hang Xu, Yutao Cui, Guangkai Ren, He Liu, Yanbing Wang, Chuangang Peng, Dankai Wu. Screening and Bioinformatics Analysis of Core Genes of Osteoporosis [J]. Chinese Journal of Geriatric Orthopaedics and Rehabilitation(Electronic Edition), 2023, 09(01): 18-22.
[12]	Xuefen Chen, Jingmin Deng. Literature review of 179 cases of primary pulmonary lymphoepithelioma-like carcinoma in the last 30 years [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(05): 551-556.
[13]	Fei Kong, Fabing Tang, Qiong Wei, Shanlin Fan, Wenzhen Yuan. Surgical treamtent of giant gastrointestinal mesenchymal tumor after neoadjuvant therapy: a case report and review of the literature [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(03): 360-363.
[14]	Yicheng Guo, Zhipeng Xie, Wanli Liu, Yang Zhao, Yansheng Che, Min Zhao. Characteristic analysis of precordial referred pain caused by osteoporotic vertebral compression fracture in the 12th thoracic vertebrae misdiagnosed as coronary heart disease [J]. Chinese Journal of Diagnostics(Electronic Edition), 2023, 11(02): 136-139.
[15]	Xiaohui Bai, Long Zhang, Yongfeng Wang, Yi Feng, Bin Zhao, Zhi Lyu, Chaojian Xu. Comparison of therapeutic effects between unilateral and bilateral percutaneous vertebroplasty for Kummell's disease [J]. Chinese Journal of Geriatrics Research(Electronic Edition), 2023, 10(02): 14-18.

Please choose a citation manager

Content to export